© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
January 25, 2021
Twelve percent of patients with negative results on conventional imaging had lesion localization on 18F-fluciclovine PET.
The PD-L1 inhibitor was approved based on data from the phase 3 JAVELIN Bladder 100 study.
January 21, 2021
The GnRH receptor antagonist was approved by the FDA in December 2020 for the treatment of patients with advanced prostate cancer.
The boost improved biochemical disease-free survival without negatively affecting safety and quality of life.
The trend in prostate cancer aligns with an overall decline in cancer-related suicide across all tumor types.
January 19, 2021
The study contradicts the findings from an Italian study published in 2020.
Higher medical mistrust and concerns about masculinity likely contribute to the increased decision regret.
January 14, 2021
The integrated radiomic-clinicopathologic nomogram (RadClip) was a better prognosticator of biochemical recurrence-free survival and adverse pathology than other standard tools.
January 13, 2021
Health literacy was associated with a reduced likelihood that a patients' screening decision would be affected by the screening-promoting effects of shared decision making.
January 12, 2021
Among patients with 6 years’ follow-up, no differences were observed between ultra-hypofractionation and conventional fractionation in the rates of clinically relevant deterioration in overall urinary bother, overall bowel bother, overall sexual bother, or global health/QoL.
January 08, 2021
The investigators drew specific attention to the impact of their findings on prostate ablation therapy.
In the ARAMIS trial, darolutamide reduced the risk of death by 31% compared with placebo in men with nonmetastatic castration-resistant prostate cancer.
The technique fails to demonstrate benefits for prostate cancer recurrence and metastases.
January 07, 2021
The researchers also found evidence supporting the role of germline variation in healthcare disparities related to prostate cancer.
“Instead of just offering a select-few treatment options, ideally you would like to be able to offer patients a whole menu of treatments and have an educated conversation regarding the risks and benefits for each of these treatment options," says Rian Dickstein, MD.
January 05, 2021
The FDA approved relugolix in December 2020 for the treatment of patients with advanced prostate cancer.
January 04, 2021
The research involved examining circulating markers of inflammation in patients with prostate cancer receiving androgen-deprivation therapy.
December 30, 2020
Urology Times spoke with Raoul S. Concepcion, MD, FACS, and Christopher M. Pieczonka, MD, about advances made in the prostate cancer space in 2020.
December 29, 2020
Because of the limitations of the research, the findings need to be considered with caution, said Lourdes Guerrios-Rivera, MD, MSc.
December 23, 2020
Urologist Adam J. Gadzinski, MD, MS, shares his excitement about the dawn of the precision medicine era in prostate cancer.